01—Abstract
Summary
Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
On August 6, 2025, Edwards Lifesciences (NYSE: EW) disclosed that the U.S. Federal Trade Commission (FTC) has moved to block its proposed acquisition of JenaValve Technology, Inc., a company focused on treatments for aortic regurgitation (AR).
Edwards publicly disagrees with the FTC's decision, argues the deal would accelerate availability and innovation of AR therapies, and says it intends to keep pursuing regulatory approval, estimating a final determination by the end of Q1 2026. The filing is a Regulation FD disclosure furnishing the press release (Exhibit 99.1), so the information is not deemed "filed" under Section 18 of the Exchange Act. The most actionable item for investors is the revised 2025 guidance.
Edwards states there is no impact to revenue guidance, and it raised the high end of its full-year 2025 adjusted diluted EPS guidance to $2.45a-$2.55 from $2.40-$2.50. Management expects minimal impact on Q3 adjusted EPS guidance. The guidance change is likely tied to the deal's removal from near-term expense assumptions, but the filing does not explicitly quantify the drivers, so investors should treat that link as an inference.
The key open question is whether the transaction ultimately closes. The FTC's action introduces regulatory risk, and the outcome remains uncertain until the final determination expected by Q1 2026. The filing's forward-looking statements caution that results could differ materially, and the company does not provide a GAAP reconciliation for its non-GAAP EPS guidance.
02—Key points
Key Highlights
- FTC moved to block Edwards' proposed acquisition of JenaValve Technology; Edwards disagrees and intends to continue pursuing regulatory approval.
- Management estimates a final regulatory determination on the deal by the end of Q1 2026.
- Full-year 2025 adjusted EPS guidance raised at the high end to $2.45-$2.55 from $2.40-$2.50.
- No change to full-year 2025 revenue guidance.
- Minimal expected impact on Q3 2025 adjusted EPS guidance.
- Edwards argues the JenaValve deal would accelerate availability, adoption, and innovation of treatments for aortic regurgitation.
- Disclosed under Item 7.01 (Regulation FD) with the press release furnished as Exhibit 99.1, not deemed filed under Exchange Act Section 18.
03—Questions
Frequently Asked Questions
Why did the FTC move to block the JenaValve acquisition?
The filing does not state the FTC's specific rationale. It reports only that the FTC moved to block the deal, and Edwards disagrees, arguing the acquisition would expand access to an important aortic regurgitation treatment option. Details of the FTC's competitive concerns would be found in the agency's own materials or subsequent filings.
Does the FTC action affect Edwards' 2025 revenue outlook?
No. Edwards states there is no impact to its revenue guidance. The change is limited to adjusted EPS guidance.
Why did Edwards raise its EPS guidance if the deal is being blocked?
The filing says the increase reflects the FTC's action but does not itemize the drivers. A likely explanation is that the expected costs or dilution associated with the pending acquisition are no longer in the 2025 forecast, but this is an inference rather than a stated reason.
When will it be known whether the acquisition can proceed?
Edwards estimates a final determination by the end of the first quarter of 2026. The company says it intends to continue pursuing regulatory approval until then.
Is the revised EPS guidance based on GAAP results?
No. The guidance is non-GAAP and excludes certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. Edwards says it cannot reconcile the non-GAAP guidance to GAAP because of the unknown timing and significance of special charges or gains.
04—Continue